Quarterly report pursuant to Section 13 or 15(d)

COMMITMENTS AND CONTINGENCIES - Narrative (Details)

v3.20.2
COMMITMENTS AND CONTINGENCIES - Narrative (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Feb. 17, 2020
USD ($)
Oct. 31, 2020
USD ($)
shares
Sep. 30, 2020
USD ($)
ft²
renewal_term
Jun. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
ft²
renewal_term
Sep. 30, 2019
USD ($)
Aug. 31, 2020
Loss Contingencies [Line Items]                
Lease term               5 years
Number of additional terms | renewal_term     2     2    
Renewal term     3 years     3 years    
Area of leased property | ft²     3,038     3,038    
Monthly payment, initial year     $ 4,430     $ 4,430    
Annual payment percentage increase     3.50%     3.50%    
Monthly fees     $ 2,160     $ 2,160    
Discount rate     12.00%     12.00%    
Expected remaining term     2 years 9 months 18 days     2 years 9 months 18 days    
Amortization of operating lease right-of-use assets     $ 19,000     $ 100,000    
Remaining lease term           1 year 1 month 6 days    
Lease expense     23,000   $ 22,000 $ 100,000 $ 100,000  
Research and development     $ 1,281,000   $ 3,337,000 6,657,000 $ 13,585,000  
Bodor Laboratories, Inc.                
Loss Contingencies [Line Items]                
Non-refundable upfront fees $ 1,000,000.0              
Cash payment 1,800,000              
Payments for additional product approval 100,000              
Value of shares issued in agreement $ 1,500,000              
Milestone payment       $ 500,000        
Research and development           $ 1,500,000    
Bodor Laboratories, Inc. | Subsequent Event                
Loss Contingencies [Line Items]                
Cash payment   $ 500,000            
Value of shares issued in agreement   $ 500,000            
Shares issued in agreement (in shares) | shares   480,769